Travere Therapeutics, Inc. TVTX
Set alert
As of Nov 3, 10:14 AM ET
- YTD
- +17.89%
- 1 year
- +30.45%
- Open
- 46.52
- Prev close
- 49.26
- Mkt cap
- 4.25B
- Vol
- 2.10M
- Avg vol
- 1.79M
- EPS
- -0.74
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 44.73
- High
- 47.75
- Forward P/E
- 9.14
- Beta
- 1.12
- Short ratio
- 5.59
- Inst. own
- 116.11%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 18, 2027
- 50-d avg
- 59.06
- 200-d avg
- 46.62
- 1y target
- 75.21
5D chart
Events in this range
- Nov 2, 2026Earnings: -0.55; estimate -0.09842; surprise -458.83%
Signals (95)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Nov 3, 9:30 AM | 44 minutes ago |
| RSI: Oversold | Nov 3, 9:30 AM | 44 minutes ago |
| MACD: Sell Signal | Nov 2, 4:00 PM | 18 hours ago |
| SMA: Bearish | Nov 2, 3:55 PM | 18 hours ago |
| SMA: Bullish | Nov 2, 3:40 PM | 18 hours ago |
| SMA: Bearish | Nov 2, 3:35 PM | 18 hours ago |
| SMA: Bullish | Nov 2, 2:40 PM | 19 hours ago |
| SMA: Bullish | Nov 2, 2:40 PM | 19 hours ago |
| SMA: Bearish | Nov 2, 2:35 PM | 19 hours ago |
| SMA: Bearish | Nov 2, 2:30 PM | 19 hours ago |
| SMA: Bullish | Nov 2, 2:20 PM | 19 hours ago |
| SMA: Bearish | Nov 2, 2:15 PM | 19 hours ago |
| SMA: Bullish | Nov 2, 2:10 PM | 20 hours ago |
| SMA: Bullish | Nov 2, 2:05 PM | 20 hours ago |
| MACD: Buy Signal | Nov 2, 2:05 PM | 20 hours ago |
| MACD: Sell Signal | Nov 2, 1:30 PM | 20 hours ago |
| SMA: Bearish | Nov 2, 1:00 PM | 21 hours ago |
| SMA: Bearish | Nov 2, 1:00 PM | 21 hours ago |
| SMA: Bullish | Nov 2, 12:45 PM | 21 hours ago |
| SMA: Bullish | Nov 2, 12:45 PM | 21 hours ago |
Newest 20 of 95.
News
10 hours ago seekingalpha.com
Travere Therapeutics, Inc. (TVTX) Q3 2026 Earnings Call Transcript
Travere Therapeutics, Inc. (TVTX) Q3 2026 Earnings Call Transcript
14 hours ago zacks.com
Here's What Key Metrics Tell Us About Travere (TVTX) Q3 Earnings
The headline numbers for Travere (TVTX) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street…
14 hours ago marketbeat.com
What Travere Therapeutics (TVTX) Said on Its Q3 Earnings Call
Travere Therapeutics NASDAQ: TVTX reported third-quarter results marked by record FILSPARI sales, continued early adoption in focal segmental glomerulosclerosis (FSGS), and progress across its…
15 hours ago zacks.com
Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates
Travere Therapeutics (TVTX) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to earnings of $0.28 per share a year ago.
16 hours ago benzinga.com
Travere Therapeutics Q3 2026 Earnings Call Transcript
Travere Therapeutics (NASDAQ:TVTX) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
18 hours ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) stock moved upwards by 16.2% to $4.67 during Monday's after-market session. The market value of their outstanding shares is at $9.1 million. Cerus…
-
18 hours ago benzinga.com
Travere Therapeutics Q3 Adj. EPS $(0.31) Misses $(0.06) Estimate, Sales $224.563M Beat $195.292M Estimate
Travere Therapeutics (NASDAQ:TVTX) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.06) by 416.67 percent. This is a 152.54 percent decrease over…
18 hours ago businesswire.com
Travere Therapeutics Reports Third Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today reported its third quarter 2026 financial results and provided a corporate update. “Strong execution across our…
-
1 week ago benzinga.com
Reported Friday, Travere Says PROTECT Biomarker Data Add To Superior Proteinuria Reduction, Slower Kidney Function Decline Versus Irbesartan, Supporting FILSPARI As Non-Immunosuppressive, Kidney-Targeted, Foundational First-Line Treatment For IgA Nephropathy
FILSPARI achieved greater reductions in biomarkers linked to kidney inflammation and injury than maximum labeled dose irbesartanFindings provide further evidence of the biological effects of dual…
1 week ago benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
3 weeks ago benzinga.com
FTC Says Martin Shkreli ‘Flagrantly’ Violated Lifetime Pharma Ban With Drug Stock Trades
FTC and 7 states seek contempt against Martin Shkreli, alleging he violated his lifetime pharma ban by trading biotech stocks and influencing markets.
-
1 month ago benzinga.com
Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $89
Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $75 to $89.
-
1 month ago benzinga.com
Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $76 Price Target
Wedbush analyst Laura Chico reiterates Travere Therapeutics (NASDAQ:TVTX) with a Outperform and maintains $76 price target.
-
1 month ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $67 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Travere Therapeutics (NASDAQ:TVTX) with a Buy and maintains $67 price target.
-
1 month ago benzinga.com
Travere Therapeutics Appoints Bradley L. Campbell President, CEO, Effective Dec. 1, Succeeding Eric Dube
Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that Eric Dube, Ph.D., has made the difficult and personal decision to step down as president and chief executive officer to focus on his…
-
2 months ago benzinga.com
Evercore ISI Group Maintains Outperform on Travere Therapeutics, Raises Price Target to $78
Evercore ISI Group analyst Liisa Bayko maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $68 to $78.
-
2 months ago benzinga.com
Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $70
Canaccord Genuity analyst Edward Nash maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $62 to $70.
-
2 months ago benzinga.com
Wedbush Maintains Outperform on Travere Therapeutics, Raises Price Target to $75
Wedbush analyst Laura Chico maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $61 to $75.
-
2 months ago benzinga.com
TD Cowen Maintains Buy on Travere Therapeutics, Raises Price Target to $75
TD Cowen analyst Tyler Van Buren maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $60 to $75.
-
2 months ago benzinga.com
Citigroup Maintains Buy on Travere Therapeutics, Raises Price Target to $85
Citigroup analyst Yigal Nochomovitz maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $70 to $85.
-
2 months ago benzinga.com
Evercore ISI Group Maintains Outperform on Travere Therapeutics, Raises Price Target to $68
Evercore ISI Group analyst Liisa Bayko maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $60 to $68.
3 months ago benzinga.com
Wynn Resorts Posts Upbeat Q2 Earnings, Joins Bloomin' Brands, Shopify, Owens Corning And Other Big Stocks Moving Higher On Wednesday
US stocks rise, Wynn Resorts beat earnings expectations, share price jumps 10.9%. Other companies recording gains in today's session.
-
3 months ago benzinga.com
Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $75
Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $65 to $75.
3 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Bluejay Diagnostics (NASDAQ:BJDX) shares moved upwards by 43.0% to $1.43 during Wednesday's pre-market session. The company's market cap stands at $1.0 million. Estrella Immunopharma…
3 months ago benzinga.com
Travere Therapeutics (TVTX) Stock Rallies Over 13% After Hours: Here's What Is Going On
Travere Therapeutics shares surged 13.44% after hours as strong revenue growth and FILSPARI sales gains outweighed earnings concerns.
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Bluejay Diagnostics (NASDAQ:BJDX) stock moved upwards by 42.0% to $1.42 during Tuesday's after-market session. American Well (NYSE:AMWL) stock rose 12.76% to $11.75. The market value of their…
-
3 months ago benzinga.com
Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $62
Canaccord Genuity analyst Edward Nash maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $56 to $62.
-
4 months ago benzinga.com
Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $65
Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $56 to $65.
-
4 months ago benzinga.com
Wedbush Maintains Outperform on Travere Therapeutics, Raises Price Target to $61
Wedbush analyst Laura Chico maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $55 to $61.
-
4 months ago benzinga.com
Evercore ISI Group Maintains Outperform on Travere Therapeutics, Raises Price Target to $60
Evercore ISI Group analyst Liisa Bayko maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $52 to $60.
-
4 months ago benzinga.com
Citigroup Maintains Buy on Travere Therapeutics, Raises Price Target to $70
Citigroup analyst Yigal Nochomovitz maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $62 to $70.
-
4 months ago benzinga.com
Wells Fargo Maintains Overweight on Travere Therapeutics, Raises Price Target to $65
Wells Fargo analyst Mohit Bansal maintains Travere Therapeutics (NASDAQ:TVTX) with a Overweight and raises the price target from $50 to $65.
-
5 months ago benzinga.com
Travere Therapeutics Announces Long-Term Results From Ongoing Phase 3 DUPLEX Study Open-Label Extension Of FILSPARI In Treatment Of Focal Segmental Glomerulosclerosis
Patients in the study who initiated and remained on FILSPARI maintained durable and deepened proteinuria reductions, resulting in further achievement of clinically meaningful low proteinuria…
-
5 months ago benzinga.com
Citigroup Maintains Buy on Travere Therapeutics, Raises Price Target to $62
Citigroup analyst Yigal Nochomovitz maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $59 to $62.
-
5 months ago benzinga.com
Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $55 Price Target
Wedbush analyst Laura Chico reiterates Travere Therapeutics (NASDAQ:TVTX) with a Outperform and maintains $55 price target.
-
5 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Travere Therapeutics, Raises Price Target to $67
HC Wainwright & Co. analyst Joseph Pantginis maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $57 to $67.
-
5 months ago benzinga.com
Travere Therapeutics Enters Into Exclusive Licensing And Collaboration Agreement With Everest Medicines For Development And Commercialization Of Civorebrutinib
Civorebrutinib is an investigational oral, covalent reversible BTK inhibitor designed to provide differentiated efficacy, safety and convenience in immune-mediated kidney diseasesCivorebrutinib adds…
-
5 months ago benzinga.com
Travere Therapeutics Receives Notice Of Allowance From U.S. Patent And Trademark Office For Patent Titled Biphenyl Sulfonamide Compounds For The Treatment Of Kidney Diseases Or Disorders
Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 19/253,088, titled…
-
6 months ago benzinga.com
Wells Fargo Maintains Overweight on Travere Therapeutics, Raises Price Target to $50
Wells Fargo analyst Mohit Bansal maintains Travere Therapeutics (NASDAQ:TVTX) with a Overweight and raises the price target from $40 to $50.
-
6 months ago benzinga.com
Travere Therapeutics Plans To Offer $400M Senior Convertible Notes Due 2032
Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced its intention to offer, subject to market and other conditions, $400 million aggregate principal amount of convertible senior notes due 2032…
6 months ago benzinga.com
Travere Therapeutics Analysts Increase Their Forecasts Following Q1 Earnings
Travere Therapeutics (NASDAQ:TVTX) reported a profit in Q1, surpassing analyst estimates. Shares fell 1.1% on Tuesday, analysts have raised price targets.
-
6 months ago benzinga.com
TD Cowen Maintains Buy on Travere Therapeutics, Raises Price Target to $60
TD Cowen analyst Tyler Van Buren maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $45 to $60.
-
6 months ago benzinga.com
Citigroup Maintains Buy on Travere Therapeutics, Raises Price Target to $59
Citigroup analyst Yigal Nochomovitz maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $53 to $59.
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
6 months ago benzinga.com
Crude Oil Falls Sharply; Wells Fargo Earnings Miss Views
Dow Jones up 200 points, consumer discretionary shares rise 1.8%, Wells Fargo reports worse-than-expected earnings, Avanos Medical surges 69%.
6 months ago benzinga.com
Avanos Medical, Travere Therapeutics, Globalstar And Other Big Stocks Moving Higher On Tuesday
Dow Jones up 200 points, Avanos Medical Inc rose on going-private deal. Big gainers include AVNS, TVTX, BE, IONQ, SANA, RGTI, VACH, AOSL.
6 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
6 months ago benzinga.com
Ligand Pharmaceuticals Partner Travere Therapeutics Wins FDA Approval For First Drug Treating Rare Kidney Disease
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its partner Travere Therapeutics, Inc. (NASDAQ:TVTX) has received approval from the U.S. Food and Drug Administration (FDA) for…
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session